Immunovant Stock Probability of Future Stock Price Finishing Under 41.21

IMVT Stock  USD 28.22  0.57  1.98%   
Immunovant's future price is the expected price of Immunovant instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Immunovant performance during a given time horizon utilizing its historical volatility. Check out Immunovant Backtesting, Immunovant Valuation, Immunovant Correlation, Immunovant Hype Analysis, Immunovant Volatility, Immunovant History as well as Immunovant Performance.
For more information on how to buy Immunovant Stock please use our How to Invest in Immunovant guide.
  
At this time, Immunovant's Price Book Value Ratio is comparatively stable compared to the past year. Price Earnings To Growth Ratio is likely to gain to 3,193 in 2024, despite the fact that Price To Free Cash Flows Ratio is likely to grow to (5.00). Please specify Immunovant's target price for which you would like Immunovant odds to be computed.

Immunovant Target Price Odds to finish below 41.21

The tendency of Immunovant Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to stay under $ 41.21  after 90 days
 28.22 90 days 41.21 
close to 99
Based on a normal probability distribution, the odds of Immunovant to stay under $ 41.21  after 90 days from now is close to 99 (This Immunovant probability density function shows the probability of Immunovant Stock to fall within a particular range of prices over 90 days) . Probability of Immunovant price to stay between its current price of $ 28.22  and $ 41.21  at the end of the 90-day period is about 74.82 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.01 . This usually indicates Immunovant market returns are related to returns on the market. As the market goes up or down, Immunovant is expected to follow. Additionally Immunovant has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Immunovant Price Density   
       Price  

Predictive Modules for Immunovant

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Immunovant. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Immunovant's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
25.3027.9030.50
Details
Intrinsic
Valuation
LowRealHigh
25.4033.7636.36
Details
Naive
Forecast
LowNextHigh
27.5630.1732.77
Details
16 Analysts
Consensus
LowTargetHigh
39.9043.8548.67
Details

Immunovant Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Immunovant is not an exception. The market had few large corrections towards the Immunovant's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Immunovant, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Immunovant within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.21
β
Beta against Dow Jones1.01
σ
Overall volatility
1.54
Ir
Information ratio -0.07

Immunovant Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Immunovant for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Immunovant can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Immunovant generated a negative expected return over the last 90 days
Immunovant has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (259.34 M) with profit before overhead, payroll, taxes, and interest of 0.
Immunovant currently holds about 427.2 M in cash with (214.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.66.
Immunovant has a frail financial position based on the latest SEC disclosures
Roughly 56.0% of the company shares are held by company insiders
Latest headline from MacroaxisInsider: Disposition of 4747 shares by Barnett Eva Renee of Immunovant at 28.06 subject to Rule 16b-3

Immunovant Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Immunovant Stock often depends not only on the future outlook of the current and potential Immunovant's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Immunovant's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding138.1 M
Cash And Short Term Investments635.4 M

Immunovant Technical Analysis

Immunovant's future price can be derived by breaking down and analyzing its technical indicators over time. Immunovant Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Immunovant. In general, you should focus on analyzing Immunovant Stock price patterns and their correlations with different microeconomic environments and drivers.

Immunovant Predictive Forecast Models

Immunovant's time-series forecasting models is one of many Immunovant's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Immunovant's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Immunovant

Checking the ongoing alerts about Immunovant for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Immunovant help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Immunovant generated a negative expected return over the last 90 days
Immunovant has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (259.34 M) with profit before overhead, payroll, taxes, and interest of 0.
Immunovant currently holds about 427.2 M in cash with (214.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.66.
Immunovant has a frail financial position based on the latest SEC disclosures
Roughly 56.0% of the company shares are held by company insiders
Latest headline from MacroaxisInsider: Disposition of 4747 shares by Barnett Eva Renee of Immunovant at 28.06 subject to Rule 16b-3

Additional Tools for Immunovant Stock Analysis

When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.